Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas

Doreen N. Nguyen, Christopher M Heaphy, Roeland F. De Wilde, Brent A. Orr, Yazmin Odia, Charles G Eberhart, Alan Keith Meeker, Fausto J Rodriguez

Research output: Contribution to journalArticle

Abstract

Recent studies suggest that the telomere maintenance mechanism known as alternative lengthening of telomeres (ALT) is relatively more common in specific glioma subsets and strongly associated with ATRX mutations. We retrospectively examined 116 high-grade astrocytomas (32 pediatric glioblastomas, 65 adult glioblastomas, 19 anaplastic astrocytomas) with known ALT status using tissue microarrays to identify associations with molecular and phenotypic features. Immunohistochemistry was performed using antibodies against ATRX, DAXX, p53 and IDH1R132H mutant protein. EGFR amplification was evaluated by fluorescence in situ hybridization (FISH). Almost half of fibrillary and gemistocytic astrocytomas (44%) demonstrated ALT. Conversely all gliosarcomas (n = 4), epithelioid (n = 2), giant cell (n = 2) and adult small cell astrocytomas (n = 7) were ALT negative. The ALT phenotype was positively correlated with the presence of round cells (P = 0.002), microcysts (P <0.0002), IDH1 mutant protein (P <0.0001), ATRX protein loss (P <0.0001), strong P53 immunostaining (P <0.0001) and absence of EGFR amplification (P = 0.004). There was no significant correlation with DAXX expression. We conclude that ALT represents a specific phenotype in high-grade astrocytomas with distinctive pathologic and molecular features. Future studies are required to clarify the clinical and biological significance of ALT in high-grade astrocytomas.

Original languageEnglish (US)
Pages (from-to)237-243
Number of pages7
JournalBrain Pathology
Volume23
Issue number3
DOIs
StatePublished - May 2013

Fingerprint

Telomere Homeostasis
Astrocytoma
Phenotype
Mutant Proteins
Glioblastoma
Gliosarcoma
Telomere
Giant Cells
Fluorescence In Situ Hybridization
Glioma
Immunohistochemistry
Maintenance
Pediatrics
Mutation
Antibodies

Keywords

  • ALT
  • ATRX
  • DAXX
  • glioblastoma
  • glioma
  • telomeres

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pathology and Forensic Medicine
  • Clinical Neurology

Cite this

Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. / Nguyen, Doreen N.; Heaphy, Christopher M; De Wilde, Roeland F.; Orr, Brent A.; Odia, Yazmin; Eberhart, Charles G; Meeker, Alan Keith; Rodriguez, Fausto J.

In: Brain Pathology, Vol. 23, No. 3, 05.2013, p. 237-243.

Research output: Contribution to journalArticle

@article{6252023bb0094e068d2fac323aa7d3cb,
title = "Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas",
abstract = "Recent studies suggest that the telomere maintenance mechanism known as alternative lengthening of telomeres (ALT) is relatively more common in specific glioma subsets and strongly associated with ATRX mutations. We retrospectively examined 116 high-grade astrocytomas (32 pediatric glioblastomas, 65 adult glioblastomas, 19 anaplastic astrocytomas) with known ALT status using tissue microarrays to identify associations with molecular and phenotypic features. Immunohistochemistry was performed using antibodies against ATRX, DAXX, p53 and IDH1R132H mutant protein. EGFR amplification was evaluated by fluorescence in situ hybridization (FISH). Almost half of fibrillary and gemistocytic astrocytomas (44{\%}) demonstrated ALT. Conversely all gliosarcomas (n = 4), epithelioid (n = 2), giant cell (n = 2) and adult small cell astrocytomas (n = 7) were ALT negative. The ALT phenotype was positively correlated with the presence of round cells (P = 0.002), microcysts (P <0.0002), IDH1 mutant protein (P <0.0001), ATRX protein loss (P <0.0001), strong P53 immunostaining (P <0.0001) and absence of EGFR amplification (P = 0.004). There was no significant correlation with DAXX expression. We conclude that ALT represents a specific phenotype in high-grade astrocytomas with distinctive pathologic and molecular features. Future studies are required to clarify the clinical and biological significance of ALT in high-grade astrocytomas.",
keywords = "ALT, ATRX, DAXX, glioblastoma, glioma, telomeres",
author = "Nguyen, {Doreen N.} and Heaphy, {Christopher M} and {De Wilde}, {Roeland F.} and Orr, {Brent A.} and Yazmin Odia and Eberhart, {Charles G} and Meeker, {Alan Keith} and Rodriguez, {Fausto J}",
year = "2013",
month = "5",
doi = "10.1111/j.1750-3639.2012.00630.x",
language = "English (US)",
volume = "23",
pages = "237--243",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas

AU - Nguyen, Doreen N.

AU - Heaphy, Christopher M

AU - De Wilde, Roeland F.

AU - Orr, Brent A.

AU - Odia, Yazmin

AU - Eberhart, Charles G

AU - Meeker, Alan Keith

AU - Rodriguez, Fausto J

PY - 2013/5

Y1 - 2013/5

N2 - Recent studies suggest that the telomere maintenance mechanism known as alternative lengthening of telomeres (ALT) is relatively more common in specific glioma subsets and strongly associated with ATRX mutations. We retrospectively examined 116 high-grade astrocytomas (32 pediatric glioblastomas, 65 adult glioblastomas, 19 anaplastic astrocytomas) with known ALT status using tissue microarrays to identify associations with molecular and phenotypic features. Immunohistochemistry was performed using antibodies against ATRX, DAXX, p53 and IDH1R132H mutant protein. EGFR amplification was evaluated by fluorescence in situ hybridization (FISH). Almost half of fibrillary and gemistocytic astrocytomas (44%) demonstrated ALT. Conversely all gliosarcomas (n = 4), epithelioid (n = 2), giant cell (n = 2) and adult small cell astrocytomas (n = 7) were ALT negative. The ALT phenotype was positively correlated with the presence of round cells (P = 0.002), microcysts (P <0.0002), IDH1 mutant protein (P <0.0001), ATRX protein loss (P <0.0001), strong P53 immunostaining (P <0.0001) and absence of EGFR amplification (P = 0.004). There was no significant correlation with DAXX expression. We conclude that ALT represents a specific phenotype in high-grade astrocytomas with distinctive pathologic and molecular features. Future studies are required to clarify the clinical and biological significance of ALT in high-grade astrocytomas.

AB - Recent studies suggest that the telomere maintenance mechanism known as alternative lengthening of telomeres (ALT) is relatively more common in specific glioma subsets and strongly associated with ATRX mutations. We retrospectively examined 116 high-grade astrocytomas (32 pediatric glioblastomas, 65 adult glioblastomas, 19 anaplastic astrocytomas) with known ALT status using tissue microarrays to identify associations with molecular and phenotypic features. Immunohistochemistry was performed using antibodies against ATRX, DAXX, p53 and IDH1R132H mutant protein. EGFR amplification was evaluated by fluorescence in situ hybridization (FISH). Almost half of fibrillary and gemistocytic astrocytomas (44%) demonstrated ALT. Conversely all gliosarcomas (n = 4), epithelioid (n = 2), giant cell (n = 2) and adult small cell astrocytomas (n = 7) were ALT negative. The ALT phenotype was positively correlated with the presence of round cells (P = 0.002), microcysts (P <0.0002), IDH1 mutant protein (P <0.0001), ATRX protein loss (P <0.0001), strong P53 immunostaining (P <0.0001) and absence of EGFR amplification (P = 0.004). There was no significant correlation with DAXX expression. We conclude that ALT represents a specific phenotype in high-grade astrocytomas with distinctive pathologic and molecular features. Future studies are required to clarify the clinical and biological significance of ALT in high-grade astrocytomas.

KW - ALT

KW - ATRX

KW - DAXX

KW - glioblastoma

KW - glioma

KW - telomeres

UR - http://www.scopus.com/inward/record.url?scp=84876294049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876294049&partnerID=8YFLogxK

U2 - 10.1111/j.1750-3639.2012.00630.x

DO - 10.1111/j.1750-3639.2012.00630.x

M3 - Article

C2 - 22928601

AN - SCOPUS:84876294049

VL - 23

SP - 237

EP - 243

JO - Brain Pathology

JF - Brain Pathology

SN - 1015-6305

IS - 3

ER -